- Vaccine candidate demonstrates high efficacy at 77% in a study of children aged 5-17 months conducted in Africa
- Novavax’ Matrix-M™ adjuvant used in combination with University of Oxford malaria vaccine candidate, R21, and developed in collaboration with Serum Institute of India
- Phase 3 clinical trial to evaluate safety and efficacy begun in 4,800 participants aged 5-36 months
Novavax, Inc. today announced the pre-print publication of data from a Phase 2b clinical trial in children demonstrating 77 percent efficacy for a malaria vaccine candidate, R21, created by the University of Oxford that includes Novavax’ Matrix-M™ adjuvant and is licensed to Serum Institute of India (SII). Published online in Preprints with The Lancet, this vaccine’s high levels of protective efficacy hold promise of becoming an important tool for global malaria eradication.
The Phase 2b randomized, controlled, double-blind trial was conducted at the Clinical Research Unit of Nanoro (CRUN) / Institut de Recherche en Sciences de la Santé (IRSS), Burkina Faso, and recruited 450 participants from the catchment area of Nanoro, a setting with highly seasonal malaria transmission.
The Matrix-M component of the malaria vaccine will be manufactured and supplied to Serum Institute of India (SII) by Novavax. Under Novavax’ agreement with Serum Institute, SII has rights to use Matrix-M in the vaccine in regions where the disease is endemic and will pay Novavax royalties on its market sales of the vaccine.
Additionally, Novavax will have commercial rights to sell and distribute the Serum Institute of India (SII)-manufactured vaccine in certain countries, primarily in the travelers’ and military vaccine markets.